An announcement from Aadi Bioscience ( (AADI) ) is now available.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Aadi Bioscience has entered into a Stock Purchase Agreement with KAKEN Pharmaceutical, selling its subsidiary, including the FYARRO business, for $100 million, which will fund operations into late 2028. Additionally, Aadi has secured an exclusive license for three novel ADC assets from WuXi Biologics and announced a $100 million PIPE financing to support the development of these assets, indicating a strategic shift towards leveraging advanced ADC technologies to address unmet cancer therapeutic needs.
More about Aadi Bioscience
Aadi Bioscience operates in the biotechnology industry, focusing on developing innovative antibody-drug conjugates (ADCs) for cancer treatment. The company is involved in the commercialization and development of ADC portfolios in collaboration with global partners, targeting various cancer indications.
YTD Price Performance: 14.85%
Average Trading Volume: 128,144
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $57.18M
Find detailed analytics on AADI stock on TipRanks’ Stock Analysis page.
